NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma

• NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma

Denosumab for Smoldering Multiple Myeloma

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Sponsor

University of Rochester

Collaborator

Amgen

Location

New York

---

ClinicalTrials.gov Identifier: NCT03839459

Official Title: Denosumab for Smoldering Multiple Myeloma

First Posted : February 15, 2019

https://clinicaltrials.gov/ct2/show/NCT03839459

---

Drug: Denosumab

Denosumab: National Cancer Institute

XGEVA (denosumab) injection

---

Location

United States, New York